Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 87

1.

Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers.

Carroll DM, Murphy SE, Benowitz NL, Strasser AA, Kotlyar M, Hecht SS, Carmella SG, McClernon FJ, Pacek LR, Dermody SS, Vandrey RG, Donny EC, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2020 Feb 12. doi: 10.1158/1055-9965.EPI-19-0644. [Epub ahead of print]

PMID:
32051195
2.

Measuring the temporal association between cannabis and tobacco use among Co-using young adults using ecological momentary assessment.

Wilhelm J, Abudayyeh H, Perreras L, Taylor R, Peters EN, Vandrey R, Hedeker D, Mermelstein R, Cohn A.

Addict Behav. 2020 May;104:106250. doi: 10.1016/j.addbeh.2019.106250. Epub 2019 Dec 19. No abstract available.

PMID:
31918167
3.

The Impact of Gradual and Immediate Nicotine Reduction on Subjective Cigarette Ratings.

Smith TT, Donny EC, Luo X, Allen AM, Carroll DM, Denlinger-Apte RL, Dermody SS, Koopmeiners JS, McClernon FJ, Pacek LR, Vandrey R, Hatsukami DK.

Nicotine Tob Res. 2019 Dec 23;21(Suppl 1):S73-S80. doi: 10.1093/ntr/ntz158.

4.

Effects of Very Low Nicotine Content Cigarettes on Smoking Behavior and Biomarkers of Exposure in Menthol and Non-menthol Smokers.

Denlinger-Apte RL, Kotlyar M, Koopmeiners JS, Tidey JW, Luo X, Benowitz NL, Jensen JA, Ikuemonisan JO, Pacek LR, Smith TT, Vandrey R, Donny EC, Hatsukami DK.

Nicotine Tob Res. 2019 Dec 23;21(Suppl 1):S63-S72. doi: 10.1093/ntr/ntz160.

5.

Urinary Pharmacokinetic Profile of Cannabinoids Following Administration of Vaporized and Oral Cannabidiol and Vaporized CBD-Dominant Cannabis.

Spindle TR, Cone EJ, Kuntz D, Mitchell JM, Bigelow GE, Flegel R, Vandrey R.

J Anal Toxicol. 2019 Nov 4. pii: bkz080. doi: 10.1093/jat/bkz080. [Epub ahead of print]

PMID:
31682266
6.

Cigarette Smokers vs. Co-users of Cannabis and Cigarettes: Exposure to Toxicants.

Meier E, Vandrey R, Rubin N, Pacek LR, Jensen JA, Donny EC, Hecht SS, Carmella SG, Murphy SE, Luo X, Stepanov I, Ikuemonisan J, Severson H, al'Absi M, Hatsukami DK.

Nicotine Tob Res. 2019 Oct 16. pii: ntz199. doi: 10.1093/ntr/ntz199. [Epub ahead of print]

PMID:
31616939
7.

Cannabinoid effects on responses to quantitative sensory testing among individuals with and without clinical pain: a systematic review.

Mun CJ, Letzen JE, Peters EN, Campbell CM, Vandrey R, Gajewski-Nemes J, DiRenzo D, Caufield-Noll C, Finan PH.

Pain. 2020 Feb;161(2):244-260. doi: 10.1097/j.pain.0000000000001720.

PMID:
31613869
8.

Priority Considerations for Medicinal Cannabis-Related Research.

Bonn-Miller MO, Pollack CV Jr, Casarett D, Dart R, ElSohly M, Good L, Guzmán M, Hanuš L, Hill KP, Huestis MA, Marsh E, Sisley S, Skinner N, Spahr J, Vandrey R, Viscusi E, Ware MA, Abrams D.

Cannabis Cannabinoid Res. 2019 Sep 23;4(3):139-157. doi: 10.1089/can.2019.0045. eCollection 2019. No abstract available.

PMID:
31579832
9.

Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence.

Schuster RM, Potter K, Vandrey R, Hareli M, Gilman J, Schoenfeld D, Evins AE.

J Psychopharmacol. 2020 Feb;34(2):197-210. doi: 10.1177/0269881119872206. Epub 2019 Sep 19.

10.

Tetrahydrocannabinol Has Potential for Treating Agitation in Alzheimer's Disease.

Rosenberg PB, Outen JD, Amjad H, Burhanullah MH, Vandrey R, Monette PJ, Forester BP.

Am J Geriatr Psychiatry. 2019 Nov;27(11):1174-1176. doi: 10.1016/j.jagp.2019.05.014. Epub 2019 May 24. No abstract available.

PMID:
31196620
11.

Effects of immediate versus gradual nicotine reduction in cigarettes on biomarkers of biological effects.

Hatsukami DK, Luo X, Heskin AK, Tang MK, Carmella SG, Jensen J, Robinson JD, Vandrey R, Drobes DJ, Strasser AA, al'Absi M, Leischow S, Cinciripini PM, Koopmeiners J, Ikuemonisan J, Benowitz NL, Donny EC, Hecht SS.

Addiction. 2019 Oct;114(10):1824-1833. doi: 10.1111/add.14695. Epub 2019 Jul 8.

PMID:
31140663
12.

Urinary Excretion Profile of 11-Nor-9-Carboxy-Δ9-Tetrahydrocannabinol (THCCOOH) Following Smoked and Vaporized Cannabis Administration in Infrequent Cannabis Users.

Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, Hayes E, Vandrey R.

J Anal Toxicol. 2020 Jan 7;44(1):1-14. doi: 10.1093/jat/bkz038.

PMID:
31095692
13.

Changing landscape of cannabis: novel products, formulations, and methods of administration.

Spindle TR, Bonn-Miller MO, Vandrey R.

Curr Opin Psychol. 2019 Dec;30:98-102. doi: 10.1016/j.copsyc.2019.04.002. Epub 2019 Apr 9. Review.

PMID:
31071592
14.

Cannabidiol (CBD) content in vaporized cannabis does not prevent tetrahydrocannabinol (THC)-induced impairment of driving and cognition.

Arkell TR, Lintzeris N, Kevin RC, Ramaekers JG, Vandrey R, Irwin C, Haber PS, McGregor IS.

Psychopharmacology (Berl). 2019 Sep;236(9):2713-2724. doi: 10.1007/s00213-019-05246-8. Epub 2019 May 1.

15.

Longitudinal stability in cigarette smokers of urinary eicosanoid biomarkers of oxidative damage and inflammation.

Carmella SG, Heskin AK, Tang MK, Jensen J, Luo X, Le CT, Murphy SE, Benowitz NL, McClernon FJ, Vandrey R, Allen SS, Denlinger-Apte R, Cinciripini PM, Strasser AA, al'Absi M, Robinson JD, Donny EC, Hatsukami DK, Hecht SS.

PLoS One. 2019 Apr 25;14(4):e0215853. doi: 10.1371/journal.pone.0215853. eCollection 2019.

16.

Acute Effects of Smoked and Vaporized Cannabis in Healthy Adults Who Infrequently Use Cannabis: A Crossover Trial.

Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, Hayes E, Vandrey R.

JAMA Netw Open. 2018 Nov 2;1(7):e184841. doi: 10.1001/jamanetworkopen.2018.4841. Erratum in: JAMA Netw Open. 2018 Dec 7;1(8):e187241.

17.

Acute Pharmacokinetic Profile of Smoked and Vaporized Cannabis in Human Blood and Oral Fluid.

Spindle TR, Cone EJ, Schlienz NJ, Mitchell JM, Bigelow GE, Flegel R, Hayes E, Vandrey R.

J Anal Toxicol. 2019 May 1;43(4):233-258. doi: 10.1093/jat/bky104.

PMID:
30615181
18.

Longitudinal stability in cigarette smokers of urinary biomarkers of exposure to the toxicants acrylonitrile and acrolein.

Chen M, Carmella SG, Sipe C, Jensen J, Luo X, Le CT, Murphy SE, Benowitz NL, McClernon FJ, Vandrey R, Allen SS, Denlinger-Apte R, Cinciripini PM, Strasser AA, al'Absi M, Robinson JD, Donny EC, Hatsukami D, Hecht SS.

PLoS One. 2019 Jan 4;14(1):e0210104. doi: 10.1371/journal.pone.0210104. eCollection 2019.

19.

Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.

Lee DC, Schlienz NJ, Peters EN, Dworkin RH, Turk DC, Strain EC, Vandrey R.

Drug Alcohol Depend. 2019 Jan 1;194:500-517. doi: 10.1016/j.drugalcdep.2018.10.020. Epub 2018 Nov 15.

20.

Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial.

Hatsukami DK, Luo X, Jensen JA, al'Absi M, Allen SS, Carmella SG, Chen M, Cinciripini PM, Denlinger-Apte R, Drobes DJ, Koopmeiners JS, Lane T, Le CT, Leischow S, Luo K, McClernon FJ, Murphy SE, Paiano V, Robinson JD, Severson H, Sipe C, Strasser AA, Strayer LG, Tang MK, Vandrey R, Hecht SS, Benowitz NL, Donny EC.

JAMA. 2018 Sep 4;320(9):880-891. doi: 10.1001/jama.2018.11473.

21.

The cannabis conundrum: steering policy and medicine with insufficient data.

Vandrey R.

Int Rev Psychiatry. 2018 Jun;30(3):181-182. doi: 10.1080/09540261.2018.1491107. No abstract available.

PMID:
30179536
22.

Cannabis and cannabinoid drug development: evaluating botanical versus single molecule approaches.

Bonn-Miller MO, ElSohly MA, Loflin MJE, Chandra S, Vandrey R.

Int Rev Psychiatry. 2018 Jun;30(3):277-284. doi: 10.1080/09540261.2018.1474730.

23.

Sleep Management Among Patients with Substance Use Disorders.

Chakravorty S, Vandrey RG, He S, Stein MD.

Med Clin North Am. 2018 Jul;102(4):733-743. doi: 10.1016/j.mcna.2018.02.012. Review.

24.

The effect of high-dose dronabinol (oral THC) maintenance on cannabis self-administration.

Schlienz NJ, Lee DC, Stitzer ML, Vandrey R.

Drug Alcohol Depend. 2018 Jun 1;187:254-260. doi: 10.1016/j.drugalcdep.2018.02.022. Epub 2018 Apr 17.

25.

"Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs.

Barrett FS, Schlienz NJ, Lembeck N, Waqas M, Vandrey R.

Cannabis Cannabinoid Res. 2018 Mar 1;3(1):85-93. doi: 10.1089/can.2017.0052. eCollection 2018.

26.

Effects of reduced nicotine content cigarettes on individual withdrawal symptoms over time and during abstinence.

Dermody SS, McClernon FJ, Benowitz N, Luo X, Tidey JW, Smith TT, Vandrey R, Hatsukami D, Donny EC.

Exp Clin Psychopharmacol. 2018 Jun;26(3):223-232. doi: 10.1037/pha0000179. Epub 2018 Mar 5.

27.

Pharmacokinetic Characterization of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in Urine Following Acute Oral Cannabis Ingestion in Healthy Adults.

Schlienz NJ, Cone EJ, Herrmann ES, Lembeck NA, Mitchell JM, Bigelow GE, Flegel R, LoDico CP, Hayes ED, Vandrey R.

J Anal Toxicol. 2018 May 1;42(4):232-247. doi: 10.1093/jat/bkx102.

28.

Labeling Accuracy of Cannabidiol Extracts Sold Online.

Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R.

JAMA. 2017 Nov 7;318(17):1708-1709. doi: 10.1001/jama.2017.11909. No abstract available.

29.

Cannabis Withdrawal: A Review of Neurobiological Mechanisms and Sex Differences.

Schlienz NJ, Budney AJ, Lee DC, Vandrey R.

Curr Addict Rep. 2017 Jun;4(2):75-81. doi: 10.1007/s40429-017-0143-1. Epub 2017 Apr 29.

30.

Training and Practices of Cannabis Dispensary Staff.

Haug NA, Kieschnick D, Sottile JE, Babson KA, Vandrey R, Bonn-Miller MO.

Cannabis Cannabinoid Res. 2016 Dec 1;1(1):244-251. doi: 10.1089/can.2016.0024. eCollection 2016.

31.

Sleep continuity, architecture and quality among treatment-seeking cannabis users: An in-home, unattended polysomnographic study.

Pacek LR, Herrmann ES, Smith MT, Vandrey R.

Exp Clin Psychopharmacol. 2017 Aug;25(4):295-302. doi: 10.1037/pha0000126.

32.

Perceived nicotine content of reduced nicotine content cigarettes is a correlate of perceived health risks.

Pacek LR, Joseph McClernon F, Denlinger-Apte RL, Mercincavage M, Strasser AA, Dermody SS, Vandrey R, Smith TT, Nardone N, Hatsukami DK, Koopmeiners JS, Kozink RV, Donny EC.

Tob Control. 2018 Jul;27(4):420-426. doi: 10.1136/tobaccocontrol-2017-053689. Epub 2017 Jul 22.

33.

Morning administration of oral methamphetamine dose-dependently disrupts nighttime sleep in recreational stimulant users.

Herrmann ES, Johnson PS, Bruner NR, Vandrey R, Johnson MW.

Drug Alcohol Depend. 2017 Sep 1;178:291-295. doi: 10.1016/j.drugalcdep.2017.05.013. Epub 2017 Jun 20.

PMID:
28686987
34.

A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults.

Gray KM, Sonne SC, McClure EA, Ghitza UE, Matthews AG, McRae-Clark AL, Carroll KM, Potter JS, Wiest K, Mooney LJ, Hasson A, Walsh SL, Lofwall MR, Babalonis S, Lindblad RW, Sparenborg S, Wahle A, King JS, Baker NL, Tomko RL, Haynes LF, Vandrey RG, Levin FR.

Drug Alcohol Depend. 2017 Aug 1;177:249-257. doi: 10.1016/j.drugalcdep.2017.04.020. Epub 2017 Jun 10.

35.

Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients.

Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO.

Addict Behav. 2017 Sep;72:14-20. doi: 10.1016/j.addbeh.2017.03.006. Epub 2017 Mar 9.

36.

Pharmacokinetic Profile of Oral Cannabis in Humans: Blood and Oral Fluid Disposition and Relation to Pharmacodynamic Outcomes.

Vandrey R, Herrmann ES, Mitchell JM, Bigelow GE, Flegel R, LoDico C, Cone EJ.

J Anal Toxicol. 2017 Mar 1;41(2):83-99. doi: 10.1093/jat/bkx012.

37.

Reducing nicotine exposure results in weight gain in smokers randomised to very low nicotine content cigarettes.

Rupprecht LE, Koopmeiners JS, Dermody SS, Oliver JA, al'Absi M, Benowitz NL, Denlinger-Apte R, Drobes DJ, Hatsukami D, McClernon FJ, Pacek LR, Smith TT, Sved AF, Tidey J, Vandrey R, Donny EC.

Tob Control. 2017 Mar;26(e1):e43-e48. doi: 10.1136/tobaccocontrol-2016-053301. Epub 2016 Nov 17.

38.

Response to varying the nicotine content of cigarettes in vulnerable populations: an initial experimental examination of acute effects.

Higgins ST, Heil SH, Sigmon SC, Tidey JW, Gaalema DE, Stitzer ML, Durand H, Bunn JY, Priest JS, Arger CA, Miller ME, Bergeria CL, Davis DR, Streck JM, Zvorsky I, Redner R, Vandrey R, Pacek LR.

Psychopharmacology (Berl). 2017 Jan;234(1):89-98. doi: 10.1007/s00213-016-4438-z. Epub 2016 Oct 6.

39.

Effects of 6-Week Use of Reduced-Nicotine Content Cigarettes in Smokers With and Without Elevated Depressive Symptoms.

Tidey JW, Pacek LR, Koopmeiners JS, Vandrey R, Nardone N, Drobes DJ, Benowitz NL, Dermody SS, Lemieux A, Denlinger RL, Cassidy R, al'Absi M, Hatsukami DK, Donny EC.

Nicotine Tob Res. 2017 Jan;19(1):59-67. Epub 2016 Aug 3.

40.

Evaluation of a reduced nicotine product standard: Moderating effects of and impact on cannabis use.

Pacek LR, Vandrey R, Dermody SS, Denlinger-Apte RL, Lemieux A, Tidey JW, McClernon FJ, Bangdiwala AS, Drobes DJ, al'Absi M, Strasser AA, Koopmeiners JS, Hatsukami DK, Donny EC.

Drug Alcohol Depend. 2016 Oct 1;167:228-32. doi: 10.1016/j.drugalcdep.2016.08.620. Epub 2016 Aug 28.

41.

A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users.

Schuster RM, Hanly A, Gilman J, Budney A, Vandrey R, Evins AE.

Drug Alcohol Depend. 2016 Oct 1;167:199-206. doi: 10.1016/j.drugalcdep.2016.08.622. Epub 2016 Aug 28.

42.

Assessing the Validity of Online Drug Forums as a Source for Estimating Demographic and Temporal Trends in Drug Use.

Paul MJ, Chisolm MS, Johnson MW, Vandrey RG, Dredze M.

J Addict Med. 2016 Sep-Oct;10(5):324-30. doi: 10.1097/ADM.0000000000000238.

PMID:
27466069
43.

Estimations and predictors of non-compliance in switchers to reduced nicotine content cigarettes.

Nardone N, Donny EC, Hatsukami DK, Koopmeiners JS, Murphy SE, Strasser AA, Tidey JW, Vandrey R, Benowitz NL.

Addiction. 2016 Dec;111(12):2208-2216. doi: 10.1111/add.13519. Epub 2016 Aug 1.

44.

The Impact of Smoking Very Low Nicotine Content Cigarettes on Alcohol Use.

Dermody SS, Tidey JW, Denlinger RL, Pacek LR, al'Absi M, Drobes DJ, Hatsukami DK, Vandrey R, Donny EC.

Alcohol Clin Exp Res. 2016 Mar;40(3):606-15. doi: 10.1111/acer.12980. Epub 2016 Feb 25.

45.

Zonisamide Reduces Withdrawal Symptoms But Does Not Enhance Varenicline-Induced Smoking Cessation.

Dunn KE, Marcus TF, Kim C, Schroeder JR, Vandrey R, Umbricht A.

Nicotine Tob Res. 2016 May;18(5):1171-9. doi: 10.1093/ntr/ntv236. Epub 2015 Oct 17.

46.

Sex differences in cannabis withdrawal symptoms among treatment-seeking cannabis users.

Herrmann ES, Weerts EM, Vandrey R.

Exp Clin Psychopharmacol. 2015 Dec;23(6):415-21. doi: 10.1037/pha0000053. Epub 2015 Oct 12.

47.

Randomized Trial of Reduced-Nicotine Standards for Cigarettes.

Donny EC, Denlinger RL, Tidey JW, Koopmeiners JS, Benowitz NL, Vandrey RG, al'Absi M, Carmella SG, Cinciripini PM, Dermody SS, Drobes DJ, Hecht SS, Jensen J, Lane T, Le CT, McClernon FJ, Montoya ID, Murphy SE, Robinson JD, Stitzer ML, Strasser AA, Tindle H, Hatsukami DK.

N Engl J Med. 2015 Oct;373(14):1340-9. doi: 10.1056/NEJMsa1502403.

48.

Plasma Cannabinoid Pharmacokinetics After Controlled Smoking and Ad libitum Cannabis Smoking in Chronic Frequent Users.

Lee D, Bergamaschi MM, Milman G, Barnes AJ, Queiroz RH, Vandrey R, Huestis MA.

J Anal Toxicol. 2015 Oct;39(8):580-7. doi: 10.1093/jat/bkv082.

49.

Mobile App-Delivered Cognitive Behavioral Therapy for Insomnia: Feasibility and Initial Efficacy Among Veterans With Cannabis Use Disorders.

Babson KA, Ramo DE, Baldini L, Vandrey R, Bonn-Miller MO.

JMIR Res Protoc. 2015 Jul 17;4(3):e87. doi: 10.2196/resprot.3852.

50.

Cannabis species and cannabinoid concentration preference among sleep-disturbed medicinal cannabis users.

Belendiuk KA, Babson KA, Vandrey R, Bonn-Miller MO.

Addict Behav. 2015 Nov;50:178-81. doi: 10.1016/j.addbeh.2015.06.032. Epub 2015 Jun 23.

PMID:
26151582

Supplemental Content

Loading ...
Support Center